COVID-19 Vaccine Combos Aim to Boost Immunity
COVID-19 Vaccine Combos Aim to Boost Immunity
Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.
COVID-19 Vaccine Combos Aim to Boost Immunity
COVID-19 Vaccine Combos Aim to Boost Immunity

Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.

Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.

immunity
COVID-19 Hospitalizations Tank a Month After Vaccines Roll Out
COVID-19 Hospitalizations Tank a Month After Vaccines Roll Out
Asher Jones | Feb 23, 2021
Two preliminary reports from the UK provide real-world evidence in support of the Pfizer/BioNTech and Oxford-AstraZeneca vaccines.
Moderna Developing Booster Shot for New Virus Variant B.1.351
Moderna Developing Booster Shot for New Virus Variant B.1.351
Asher Jones | Jan 25, 2021
New data suggest that the company’s approved COVID-19 vaccine protects against different virus variants, but could be less effective against the one that originated in South Africa.
Introducing Inoculation, 1721
Introducing Inoculation, 1721
Max Kozlov | Jan 1, 2021
As a deadly smallpox outbreak ravaged Boston, one of the city’s leaders advocated for a preventive measure he’d learned about from Onesimus, an enslaved man.
Thwarting AAV-Neutralizing Antibodies Could Improve Gene Therapy
Thwarting AAV-Neutralizing Antibodies Could Improve Gene Therapy
Emma Yasinski | Sep 25, 2020
Adeno-associated viral vectors can deliver gene therapies, but AAV-neutralizing antibodies might prevent the medicines from working.
Vector-Based Vaccines Come to the Fore in the COVID-19 Pandemic
Vector-Based Vaccines Come to the Fore in the COVID-19 Pandemic
Anthony King | Sep 8, 2020
Adenovirus vectors deliver the genetic instructions for SARS-CoV-2 antigens directly into patients’ cells, provoking a robust immune response. But will pre-existing immunity from common colds take them down?
COVID-19 Antibodies Last for at Least Four Months After Recovery
COVID-19 Antibodies Last for at Least Four Months After Recovery
Amanda Heidt | Sep 2, 2020
The results from a study in Iceland can’t say if a recovered patient’s antibodies can protect them from subsequent reinfection.
Patients Reinfected with Coronavirus in Hong Kong, Europe
Patients Reinfected with Coronavirus in Hong Kong, Europe
Lisa Winter | Aug 25, 2020
So far, there are three patients known to have been infected with SARS-CoV-2 twice, and in at least one case the second time around was asymptomatic.
Some COVID-19 Patients Lack Key Structures for Antibody Creation
Some COVID-19 Patients Lack Key Structures for Antibody Creation
Katarina Zimmer | Aug 25, 2020
An absence of germinal centers—which arise during infections to produce long-lived antibody-generating cells—might explain rapidly waning antibody levels in the disease.
Differences in Antibody Responses Linked to COVID-19 Outcomes
Differences in Antibody Responses Linked to COVID-19 Outcomes
Katarina Zimmer | Aug 18, 2020
In a small study of patients hospitalized due to SARS-CoV-2 infection, researchers report distinct early differences between the antibody responses of patients who recovered and those who died, possibly paving the way for a tool to predict disease prognosis.
Cold-Causing Coronaviruses Don’t Seem to Confer Lasting Immunity
Cold-Causing Coronaviruses Don’t Seem to Confer Lasting Immunity
Shawna Williams | Aug 18, 2020
Studies on SARS-CoV-2’s milder cousins hint that our immune systems are quick to forget the viruses, but it’s unclear whether the same is true for the agent that causes COVID-19.
Does the Common Cold Protect You from COVID-19?
Does the Common Cold Protect You from COVID-19?
Chris Baraniuk | Aug 4, 2020
There are emerging signs that some people might have heightened protection against SARS-CoV-2, perhaps thanks to recent infection by other coronaviruses.
Studies Report Rapid Loss of COVID-19 Antibodies
Studies Report Rapid Loss of COVID-19 Antibodies
Amanda Heidt | Jun 19, 2020
The results, while preliminary, suggest that survivors of SARS-CoV-2 infection may be susceptible to reinfection within weeks or months.
Neutrophil Extracellular Traps May Augur Severe COVID-19
Neutrophil Extracellular Traps May Augur Severe COVID-19
Alakananda Dasgupta | May 28, 2020
These webs of chromatin and proteins, released by immune cells to control microbial infections, could serve as a therapeutic target in coronavirus infections.
COVID-19 Vaccine Researchers Mindful of Immune Enhancement
COVID-19 Vaccine Researchers Mindful of Immune Enhancement
Katarina Zimmer | May 26, 2020
There is no evidence that any of the coronavirus vaccines in development worsen a coronavirus infection rather than confer immunity to it, but the phenomenon is something scientists are closely monitoring.
SARS-CoV-2–Fighting T Cells Found in Recovered Patients
SARS-CoV-2–Fighting T Cells Found in Recovered Patients
Shawna Williams | May 15, 2020
While the finding doesn’t prove people become immune to the virus after infection, it is good news for vaccine development.
special report
Why the Accuracy of SARS-CoV-2 Antibody Tests Varies So Much
Why the Accuracy of SARS-CoV-2 Antibody Tests Varies So Much
Diana Kwon | May 5, 2020
The FDA cracks down on test makers as independent evaluations of their products’ performance show a need for improvement.
Opinion: Public Health Trumps Privacy in a Pandemic
Opinion: Public Health Trumps Privacy in a Pandemic
John D. Loike, Ruth L. Fischbach | Apr 16, 2020
If governments were to use SARS-CoV-2 antibody tests to manage who can re-enter the workplace, society must accept a sacrifice of privacy.
Special Report
What Do Antibody Tests For SARS-CoV-2 Tell Us About Immunity?
What Do Antibody Tests For SARS-CoV-2 Tell Us About Immunity?
Katarina Zimmer | Apr 15, 2020
Studies from serum samples could transform our understanding of the spread of COVID-19, but what antibodies alone say about immunity is not yet clear.
COVID-19 Vaccine Developers Gain Enhanced Access to Supercomputers
COVID-19 Vaccine Developers Gain Enhanced Access to Supercomputers
Lisa Winter | Mar 27, 2020
Federal agencies, academic institutions, and industrial partners are joining forces to combat COVID-19 using artificial intelligence.